Company Overview
Century Therapeutics, Inc. is a biotechnology firm dedicated to the development of allogeneic cell therapies designed to treat solid tumors, hematological malignancies, and autoimmune diseases. The company operates within the Healthcare sector and the specific Biotechnology industry, a landscape characterized by high innovation requirements and significant regulatory scrutiny. As of the latest available data, the enterprise holds a market capitalization of $372.03M, generates annual revenue of $109.16M, and employs a workforce of 78 individuals. These financial metrics suggest a mid-sized operational scale within the biotechnology niche, where revenue figures indicate a current revenue-generating phase despite the long development cycles typical for cell therapy candidates like CNTY-813. The combination of a market cap in the high hundreds of millions with a revenue base exceeding one hundred million positions the company as an established player attempting to transition from research phases toward commercialization, while maintaining a lean operational footprint of less than 100 employees.
Financial Health
The company reported revenue of $109.16M over the trailing twelve months, yet recorded a net income loss of $9,580,000 and an EBITDA of $-1,939,000. The substantial gap between the $109.16M in revenue and the negative $9,580,000 in net income reveals a cost structure dominated by research and development expenses that heavily outweigh gross profits currently generated. Free cash flow stands at $-97,213,000, indicating a significant cash burn rate that necessitates ongoing capital raises or utilization of existing cash reserves to maintain operations and fund clinical trials. Analyzing the profitability margins, the gross margin is 12.4%, while the operating margin is -13.8% and the profit margin is -8.8%, all reflecting the pre-profitability status common in late-stage biotechnology development. On the balance sheet, the company holds $117.11M in cash against $43.56M in debt, supported by a debt-to-equity ratio of 27.41 which, despite the debt figure, suggests a relatively conservative leverage profile given the cash cushion. Liquidity is robust as evidenced by a current ratio of 5.97, indicating the firm possesses more than five times the current assets required to meet its short-term liabilities. Return on Equity is -6.0% and Return on Assets is -3.3%, metrics that reveal management is currently deploying capital to generate growth rather than immediate shareholder returns, a typical pattern for companies in the biotechnology industry focused on asset development.
Valuation Assessment
Valuation metrics for Century Therapeutics, Inc. present a mixed picture typical of loss-making biotechnology firms, with a P/E Ratio (TTM) listed as N/A and a Forward P/E of -3.91. The negative forward P/E implies that earnings are currently negative, and the distinction between the unavailable trailing P/E and the negative forward P/E highlights the market's reliance on future earnings potential rather than current profitability. The price-to-book ratio is 1.14, indicating that the market values the company at a slight premium over its book value, suggesting confidence in the intangible assets and pipeline potential despite current losses. Alternative valuation measures include a price-to-sales ratio of 3.41 and an EV/EBITDA of -153.93, which suggest the market is pricing the stock based on revenue generation and future clinical success rather than immediate cash flow or earnings multiples. Price action over the last year shows a 52-week high of $3.04 and a 52-week low of $0.34, with the current trading price sitting significantly closer to the low end of this range relative to the high. The stock exhibits a beta of 1.72, which signifies that the share price is expected to be 72% more volatile than the broader market, reflecting the high risk profile associated with biotechnology equities.
Growth & Income
Growth metrics indicate a Revenue Growth (YoY) of -100.0% and an Earnings Growth (YoY) of N/A, reflecting a transition period where reported revenue may have normalized or shifted while earnings remain negative due to heavy investment costs. Because earnings are currently negative, the concept of earnings growing faster or slower than revenue is not applicable in a traditional sense, as the company is prioritizing capital expenditure for clinical development over immediate profitability. As a non-dividend payer, the company does not distribute a dividend yield or a payout ratio, which is consistent with the strategy of reinvesting all available earnings and cash reserves into research and development to advance the pipeline. The overall growth and income profile is characterized by a lack of current income generation and negative year-over-year revenue trends, which is standard for a biotechnology company focused on high-risk, high-reward therapeutic development rather than immediate cash flow stability.